Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine

NCT ID
NCT07780136
Registry status
Not yet recruiting
Study type
Interventional
Phase
Phase 4
Sponsor
Assiut University
Conditions
Chronic Migraine Headache

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: Comparison of the Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine

Enrollment: 70 participants (Estimated).

What is being studied

  • Intervention: Amino Acids, Peptides, and Proteins
  • Intervention: Bacterial Proteins
  • Intervention: Bacterial Toxins
  • Intervention: Biological Factors
  • Intervention: Botulinum Toxins
  • Intervention: Botulinum Toxins, Type A
  • Intervention: Endopeptidases
  • Intervention: Enzymes
  • Intervention: Enzymes and Coenzymes
  • Intervention: Hydrolases
  • Intervention: Metalloendopeptidases
  • Intervention: Metalloproteases
  • Drug: OnabotulinumtoxinA
  • Intervention: Peptide Hydrolases
  • Intervention: Proteins
  • Intervention: Toxins, Biological
  • Procedure: Ultrasound-guided pulsed radiofrequency (PRF)

Who may be eligible

Ages
18 Years to 65 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * • Age between 18 and 65 years, either sex. * Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria (headache occurring on ≥15 days/month for \>3 months, with migrainous features on ≥8 days/month). * Inadequate response, intolerance, or contraindication to at least one standard oral preventive medication (e.g., amitriptyline, propranolol, topiramate, flunarizine, valproate). * Stable dose of any concurrent prophylactic medication for at least 4 weeks prior to enrolment, with no planned change during the study period. * Willingness and ability to complete headache diaries and follow-up visits. Exclusion Criteria: * • Other primary headache disorders (tension-type headache, cluster headache, hemicrania continua) as the predominant headache type. * Secondary headache due to an identifiable structural, infectious, vascular, or neoplastic cause (confirmed or suspected by history/imaging). * Prior botulinum toxin injection or radiofrequency procedure for headache within the last 6 months. * Known hypersensitivity or allergy to botulinum toxin or to local anesthetics. * Pregnancy or lactation. * Neuromuscular junction disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome). * Medication overuse headache not resolved prior to enrolment.

Study locations

No study locations are listed in the registry data.

Study details

Start date
October 1, 2026
Primary completion date
October 1, 2026
Completion date
December 1, 2026
First posted
August 21, 2026

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07780136
Registry last updated
September 22, 2026
QualifiedStudies registry data refreshed
October 5, 2026
QualifiedStudies record fetched
October 5, 2026

View NCT07780136 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Migraines studies | Clinical trial FAQ